Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
[This corrects the article DOI: 10.3389/fvets.2024.1235183.].
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11816352 | PMC |
| http://dx.doi.org/10.3389/fvets.2025.1560103 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Corrigendum to "Patients with type 2 diabetes who achieve reduced postprandial glucose levels during insulin intensive therapy may have a better recovery of β-cell function". [Diabetes Res. Clin. Pract. 215 (2024) 111805].
Diabetes Res Clin Pract
September 2025
Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China. Electronic address:
Corrigendum to "Assessing CO₂ sources and sinks in and around Taiwan: Implication for achieving regional carbon neutrality by 2050" [Mar. Pollut. Bull. 206 (2024) 116664].
Mar Pollut Bull
November 2025
Department of Oceanography, National Sun Yat-sen University, Kaohsiung 80424, Taiwan, ROC.; Department of Applied Science, R.O.C. Naval Academy, Kaohsiung 81345, Taiwan, ROC.. Electronic address:
Corrigendum: Fast and convenient delivery of fluidextracts liquorice through electrospun core-shell nanohybrids.
Front Bioeng Biotechnol
June 2025
Department of Outpatient, The Third Affiliated Hospital, Naval Medical University, Shanghai, China.
[This corrects the article DOI: 10.3389/fbioe.2023.
View Article and Find Full Text PDFCorrigendum to "Computing accurate bond dissociation energies of emerging per- and polyfluoroalkyl substances: Achieving chemical accuracy using connectivity-based hierarchy schemes".
J Hazard Mater
June 2025
Department of Chemistry, Indian Institute of Technology Madras, Chennai 600036, India; Centre for Atomistic Modelling and Materials Design, Indian Institute of Technology Madras, Chennai 600036, India; Centre for Molecular Materials and Functions, Indian Institute of Technology Madras, Chennai 60003
Corrigendum to "Optimising outcomes for adults with Cystic Fibrosis taking CFTR modulators by individualising care: Personalised data linkage to understand treatment optimisation (PLUTO), a novel clinical framework" [Respirat. Med. 239 (2025)].
Respir Med
May 2025
Adult CF Centre, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK; Division of Population Health, School of Medicine and Population Health, The University of Sheffield, UK.
Cystic Fibrosis (CF) is a life-limiting, inherited condition in which a novel class of oral medicine, CFTR modulators, has revolutionised symptoms and health indicators, providing an opportunity to evaluate traditional treatment regimens with the hope of reducing burden. Additionally, there is cautious optimism that life expectancy for people with CF born today could ultimately compare to that of the general population. Given this potential, there is a need and requirement to optimise treatment to balance burden with the best clinical outcomes for each person with CF in an individualised manner.
View Article and Find Full Text PDF